---
document_datetime: 2025-12-29 10:24:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/artesunate-amivas.html
document_name: artesunate-amivas.html
version: success
processing_time: 0.1098338
conversion_datetime: 2025-12-31 01:24:26.054435
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Artesunate Amivas

[RSS](/en/individual-human-medicine.xml/67480)

##### Authorised

This medicine is authorised for use in the European Union

artesunate Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Artesunate Amivas](#news-on)
- [More information on Artesunate Amivas](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Artesunate Amivas is a malaria medicine used as initial treatment of severe malaria in adults and children. Malaria is an infection caused by a parasite known as Plasmodium. 'Severe' malaria means the disease involves potentially life-threatening symptoms.

Malaria is rare in the EU, and Artesunate Amivas was designated an 'orphan medicine' (a medicine used in rare diseases) on 28 February 2020.

Artesunate Amivas contains the active substance artesunate.

Expand section

Collapse section

## How is Artesunate Amivas used?

Artesunate Amivas can only be obtained with a prescription, and prescribers should take into account official guidance on the use of antimalarial agents. The medicine should only be used after consultation with a doctor experienced in the management of malaria.

The medicine is available as a powder and solvent to be made up into a solution for injection into a vein. The recommended dose is based on the patient's weight and should be given every 12 hours during the first 24 hours (0, 12 and 24 hours). Treatment with Artesunate Amivas should continue with one injection every 24 hours until the patient is able to take appropriate malaria treatment by mouth.

For more information about using Artesunate Amivas, see the package leaflet or contact your doctor or pharmacist.

## How does Artesunate Amivas work?

The active substance in Artesunate Amivas, artesunate, is a derivative of the naturally occurring substance artemisinin. Its exact mode of action is not fully understood, but once it has entered blood cells infected by the malaria parasite, the medicine is thought to form toxic substances called 'free radicals' that kill the parasite.

## What benefits of Artesunate Amivas have been shown in studies?

Two main studies showed that initial treatment with injectable artesunate was more effective than that with another malaria medicine, quinine, in reducing the risk of death in hospitalised patients with severe malaria.

The first study involved 1,461 adults and children. Patients received injectable treatment until they were able to receive treatment by mouth, either with Artesunate Amivas or with quinine. The results showed that 107 out of 730 (14.7%) patients who received initial treatment with Artesunate Amivas died in hospital compared with 164 out of 731 (22.4%) of those who received initial treatment with quinine.

In the second study, which involved 5,425 children under 15 years of age hospitalised with malaria, 230 out of 2712 (8.5%) patients who received Artesunate Amivas by injection followed by treatment with the malaria medicine artemether-lumefantrine died in hospital compared with 297 out of 2713 (10.9%) of those who received quinine by injection followed by artemether-lumefantrine.

## What are the risks associated with Artesunate Amivas?

The most common side effects with Artesunate Amivas (which may affect more than 1 in 10 people) are anaemia (low levels of red blood cells), reticulocytopenia (low levels of reticulocytes, a type of immature red blood cell) and post-artesunate delayed haemolysis (breakdown of red blood cells at least seven days after starting artesunate treatment, which may cause anaemia).

For the full list of side effects and restrictions of Artesunate Amivas, see the package leaflet.

## Why is Artesunate Amivas authorised in the EU?

Two studies have shown that initial treatment with Artesunate Amivas given by injection improves in-hospital survival in adults and children with severe malaria compared with quinine given by injection. The safety profile of Artesunate Amivas when given by injection into a vein was considered acceptable. The European Medicines Agency therefore decided that Artesunate Amivas's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Artesunate Amivas?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Artesunate Amivas have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Artesunate Amivas are continuously monitored. Suspected side effects reported with Artesunate Amivas are carefully evaluated and any necessary action taken to protect patients.

## Other information about Artesunate Amivas

Artesunate Amivas received a marketing authorisation valid throughout the EU on 22 November 2021.

Artesunate Amivas : EPAR - Medicine overview

Reference Number: EMA/531550/2021

English (EN) (128.53 KB - PDF)

**First published:** 04/01/2022

[View](/en/documents/overview/artesunate-amivas-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-95)

български (BG) (141.71 KB - PDF)

**First published:**

04/01/2022

[View](/bg/documents/overview/artesunate-amivas-epar-medicine-overview_bg.pdf)

español (ES) (117.89 KB - PDF)

**First published:**

04/01/2022

[View](/es/documents/overview/artesunate-amivas-epar-medicine-overview_es.pdf)

čeština (CS) (139.94 KB - PDF)

**First published:**

04/01/2022

[View](/cs/documents/overview/artesunate-amivas-epar-medicine-overview_cs.pdf)

dansk (DA) (116.57 KB - PDF)

**First published:**

04/01/2022

[View](/da/documents/overview/artesunate-amivas-epar-medicine-overview_da.pdf)

Deutsch (DE) (120.5 KB - PDF)

**First published:**

04/01/2022

[View](/de/documents/overview/artesunate-amivas-epar-medicine-overview_de.pdf)

eesti keel (ET) (104.87 KB - PDF)

**First published:**

04/01/2022

[View](/et/documents/overview/artesunate-amivas-epar-medicine-overview_et.pdf)

ελληνικά (EL) (142.58 KB - PDF)

**First published:**

04/01/2022

[View](/el/documents/overview/artesunate-amivas-epar-medicine-overview_el.pdf)

français (FR) (118.85 KB - PDF)

**First published:**

04/01/2022

[View](/fr/documents/overview/artesunate-amivas-epar-medicine-overview_fr.pdf)

hrvatski (HR) (137.99 KB - PDF)

**First published:**

04/01/2022

[View](/hr/documents/overview/artesunate-amivas-epar-medicine-overview_hr.pdf)

italiano (IT) (115.71 KB - PDF)

**First published:**

04/01/2022

[View](/it/documents/overview/artesunate-amivas-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (147.26 KB - PDF)

**First published:**

04/01/2022

[View](/lv/documents/overview/artesunate-amivas-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (137.24 KB - PDF)

**First published:**

04/01/2022

[View](/lt/documents/overview/artesunate-amivas-epar-medicine-overview_lt.pdf)

magyar (HU) (139.53 KB - PDF)

**First published:**

04/01/2022

[View](/hu/documents/overview/artesunate-amivas-epar-medicine-overview_hu.pdf)

Malti (MT) (139.48 KB - PDF)

**First published:**

04/01/2022

[View](/mt/documents/overview/artesunate-amivas-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.39 KB - PDF)

**First published:**

04/01/2022

[View](/nl/documents/overview/artesunate-amivas-epar-medicine-overview_nl.pdf)

polski (PL) (142.67 KB - PDF)

**First published:**

04/01/2022

[View](/pl/documents/overview/artesunate-amivas-epar-medicine-overview_pl.pdf)

português (PT) (118.29 KB - PDF)

**First published:**

04/01/2022

[View](/pt/documents/overview/artesunate-amivas-epar-medicine-overview_pt.pdf)

română (RO) (136.78 KB - PDF)

**First published:**

04/01/2022

[View](/ro/documents/overview/artesunate-amivas-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.44 KB - PDF)

**First published:**

04/01/2022

[View](/sk/documents/overview/artesunate-amivas-epar-medicine-overview_sk.pdf)

slovenščina (SL) (135.88 KB - PDF)

**First published:**

04/01/2022

[View](/sl/documents/overview/artesunate-amivas-epar-medicine-overview_sl.pdf)

Suomi (FI) (114.51 KB - PDF)

**First published:**

04/01/2022

[View](/fi/documents/overview/artesunate-amivas-epar-medicine-overview_fi.pdf)

svenska (SV) (103.9 KB - PDF)

**First published:**

04/01/2022

[View](/sv/documents/overview/artesunate-amivas-epar-medicine-overview_sv.pdf)

Artesunate Amivas : EPAR - Risk-management-plan summary

English (EN) (130.34 KB - PDF)

**First published:** 04/01/2022

[View](/en/documents/rmp-summary/artesunate-amivas-epar-risk-management-plan-summary_en.pdf)

## Product information

Artesunate Amivas : EPAR - Product information

English (EN) (331.35 KB - PDF)

**First published:** 04/01/2022

**Last updated:** 20/05/2025

[View](/en/documents/product-information/artesunate-amivas-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-766)

български (BG) (439.5 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/bg/documents/product-information/artesunate-amivas-epar-product-information_bg.pdf)

español (ES) (371.79 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/es/documents/product-information/artesunate-amivas-epar-product-information_es.pdf)

čeština (CS) (417.7 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/cs/documents/product-information/artesunate-amivas-epar-product-information_cs.pdf)

dansk (DA) (368.05 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/da/documents/product-information/artesunate-amivas-epar-product-information_da.pdf)

Deutsch (DE) (381.83 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/de/documents/product-information/artesunate-amivas-epar-product-information_de.pdf)

eesti keel (ET) (364.29 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/et/documents/product-information/artesunate-amivas-epar-product-information_et.pdf)

ελληνικά (EL) (655.82 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/el/documents/product-information/artesunate-amivas-epar-product-information_el.pdf)

français (FR) (381.11 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/fr/documents/product-information/artesunate-amivas-epar-product-information_fr.pdf)

hrvatski (HR) (423.2 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/hr/documents/product-information/artesunate-amivas-epar-product-information_hr.pdf)

íslenska (IS) (337.99 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/is/documents/product-information/artesunate-amivas-epar-product-information_is.pdf)

italiano (IT) (371.26 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/it/documents/product-information/artesunate-amivas-epar-product-information_it.pdf)

latviešu valoda (LV) (440.85 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/lv/documents/product-information/artesunate-amivas-epar-product-information_lv.pdf)

lietuvių kalba (LT) (429.4 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/lt/documents/product-information/artesunate-amivas-epar-product-information_lt.pdf)

magyar (HU) (442.18 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/hu/documents/product-information/artesunate-amivas-epar-product-information_hu.pdf)

Malti (MT) (472.77 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/mt/documents/product-information/artesunate-amivas-epar-product-information_mt.pdf)

Nederlands (NL) (377.97 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/nl/documents/product-information/artesunate-amivas-epar-product-information_nl.pdf)

norsk (NO) (331.16 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/no/documents/product-information/artesunate-amivas-epar-product-information_no.pdf)

polski (PL) (415.69 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/pl/documents/product-information/artesunate-amivas-epar-product-information_pl.pdf)

português (PT) (365.33 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/pt/documents/product-information/artesunate-amivas-epar-product-information_pt.pdf)

română (RO) (441.53 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/ro/documents/product-information/artesunate-amivas-epar-product-information_ro.pdf)

slovenčina (SK) (433.04 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/sk/documents/product-information/artesunate-amivas-epar-product-information_sk.pdf)

slovenščina (SL) (441.27 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/sl/documents/product-information/artesunate-amivas-epar-product-information_sl.pdf)

Suomi (FI) (371.02 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/fi/documents/product-information/artesunate-amivas-epar-product-information_fi.pdf)

svenska (SV) (366.81 KB - PDF)

**First published:**

04/01/2022

**Last updated:**

20/05/2025

[View](/sv/documents/product-information/artesunate-amivas-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000268080 20/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Artesunate Amivas : EPAR - All authorised presentations

English (EN) (79.71 KB - PDF)

**First published:** 04/01/2022

[View](/en/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-222)

български (BG) (61.62 KB - PDF)

**First published:**

04/01/2022

[View](/bg/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_bg.pdf)

español (ES) (50.65 KB - PDF)

**First published:**

04/01/2022

[View](/es/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_es.pdf)

čeština (CS) (61.88 KB - PDF)

**First published:**

04/01/2022

[View](/cs/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (52.05 KB - PDF)

**First published:**

04/01/2022

[View](/da/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (53.58 KB - PDF)

**First published:**

04/01/2022

[View](/de/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (50.2 KB - PDF)

**First published:**

04/01/2022

[View](/et/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (68.08 KB - PDF)

**First published:**

04/01/2022

[View](/el/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_el.pdf)

français (FR) (50.98 KB - PDF)

**First published:**

04/01/2022

[View](/fr/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (67.51 KB - PDF)

**First published:**

04/01/2022

[View](/hr/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (83.73 KB - PDF)

**First published:**

04/01/2022

[View](/is/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.17 KB - PDF)

**First published:**

04/01/2022

[View](/it/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (86.5 KB - PDF)

**First published:**

04/01/2022

[View](/lv/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (67.28 KB - PDF)

**First published:**

04/01/2022

[View](/lt/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (59.78 KB - PDF)

**First published:**

04/01/2022

[View](/hu/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (79.29 KB - PDF)

**First published:**

04/01/2022

[View](/mt/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (58.71 KB - PDF)

**First published:**

04/01/2022

[View](/nl/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (83.7 KB - PDF)

**First published:**

04/01/2022

[View](/no/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_no.pdf)

polski (PL) (73.1 KB - PDF)

**First published:**

04/01/2022

[View](/pl/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_pl.pdf)

português (PT) (51.42 KB - PDF)

**First published:**

04/01/2022

[View](/pt/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_pt.pdf)

română (RO) (68.14 KB - PDF)

**First published:**

04/01/2022

[View](/ro/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (69.62 KB - PDF)

**First published:**

04/01/2022

[View](/sk/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (57.78 KB - PDF)

**First published:**

04/01/2022

[View](/sl/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (49.85 KB - PDF)

**First published:**

04/01/2022

[View](/fi/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.68 KB - PDF)

**First published:**

04/01/2022

[View](/sv/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Artesunate Amivas Active substance artesunate International non-proprietary name (INN) or common name artesunate Therapeutic area (MeSH) Malaria Anatomical therapeutic chemical (ATC) code P01BE03

### Pharmacotherapeutic group

Antiprotozoals

### Therapeutic indication

Artesunate Amivas is indicated for the initial treatment of severe malaria in adults and children.

Consideration should be given to official guidance on the appropriate use of antimalarial agents.

## Authorisation details

EMA product number EMEA/H/C/005550

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Amivas Ireland Ltd

Suite 5, Second Floor

Waterford X91 P381 IRELAND

Opinion adopted 16/08/2023 Marketing authorisation issued 22/11/2021 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Artesunate Amivas : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.52 KB - PDF)

**First published:** 20/05/2025

[View](/en/documents/procedural-steps-after/artesunate-amivas-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Artesunate Amivas : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (113.37 KB - PDF)

**First published:** 24/04/2023

**Last updated:** 20/05/2025

[View](/en/documents/procedural-steps-after/artesunate-amivas-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Artesunate Amivas-H-C-PSUSA-00010958-202212 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/371965/2023

English (EN) (103.11 KB - PDF)

**First published:** 20/11/2023

[View](/en/documents/scientific-conclusion/artesunate-amivas-h-c-psusa-00010958-202212-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Artesunate Amivas : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

Reference Number: EMA/97317/2023

English (EN) (119.12 KB - PDF)

**First published:** 24/04/2023

[View](/en/documents/pip-compliance/artesunate-amivas-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

## Initial marketing authorisation documents

Artesunate Amivas : Orphan maintenance assessment report

Adopted

Reference Number: EMA/OD/0000060998

English (EN) (408.47 KB - PDF)

**First published:** 13/01/2022

[View](/en/documents/orphan-maintenance-report/artesunate-amivas-orphan-maintenance-assessment-report_en.pdf)

Artesunate Amivas : EPAR - Public assessment report

Adopted

Reference Number: EMA/584728/2021

English (EN) (2.61 MB - PDF)

**First published:** 04/01/2022

**Last updated:** 13/01/2022

[View](/en/documents/assessment-report/artesunate-amivas-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Artesunate Amivas

Adopted

Reference Number: EMA/CHMP/438991/2021

English (EN) (114.52 KB - PDF)

**First published:** 17/09/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-artesunate-amivas_en.pdf)

#### News on Artesunate Amivas

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021) 17/09/2021

#### More information on Artesunate Amivas

- [EU/3/20/2251 - orphan designation for treatment of malaria](/en/medicines/human/orphan-designations/eu-3-20-2251)

**This page was last updated on** 20/05/2025

## Share this page

[Back to top](#main-content)